InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Liminatus Pharma, Inc.

LIMN Clue Score17
United States Fiscal year ends December CIK 0001971387
$3.76 +1.90% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $3.76 +145.75% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 1 May 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2024Operating income−3.3Net income−3.5EPS, diluted−0.20Fiscal year 2025Operating income−3.0Net income−10.2EPS, diluted−0.43
FY2024FY2025
Operating income −3.3 −3.0
Net income −3.5 −10.2
Growth
EPS, diluted −0.20 −0.43
Growth

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2024Operating cash flow−1.5Fiscal year 2025Operating cash flow−10.0Capital expenditure−0.0Free cash flow−10.0
FY2024FY2025
Operating cash flow −1.5 −10.0
Capital expenditure n/a −0.0
Free cash flow n/a −10.0
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2024Cash0.0Shareholders’ equity−19.3Fiscal year 2025Shareholders’ equity−9.8
FY2024FY2025
Cash 0.0 n/a
Shareholders’ equity −19.3 −9.8

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
2.7 n/a
0.6 3.0
−3.3 −3.0
Growth
−3.5 −10.2
Growth
Per share
−0.20 −0.43
−0.20 −0.43
Growth
17.5 23.8
17.5 23.8
Growth +35.7%

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 2 of 2 years on file.